HIF-1α in colorectal carcinoma: Review of the literature

Journal of B.U.ON.

Volumn 20, Issue 3, 2015, Pages 680-689

  Ioannou, Maria ^a   Paraskeva, Efrosyni ^a   Baxevanidou, Korina ^a   Simos, George ^a   Papamichali, Roidoula ^a   Papacharalambous, Constantina ^a   Samara, Maria ^a   Koukoulis, George ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Angiogenesis; Colorectal carcinoma; HIF 1 ; Immunohistochemistry; Prognosis

Indexed keywords

APC PROTEIN; B RAF KINASE; BETA CATENIN; CETUXIMAB; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; K RAS PROTEIN; PANITUMUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; TUMOR MARKER;

CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL HYPOXIA; COLON CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL HYPOXIA; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84938676098     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Siegel EM, Jacobsen PB, Lee JH et al. Florida Initiative for Quality Cancer Care: improvements on colorectal cancer quality of care indicators during a 3-year interval. J Am Coll Surg 2014; 218:16-25.e1-4.
2. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116e129.
3. Worthley DL, Leggett BA. Colorectal Cancer: Molecular Features and Clinical Opportunities. Clin Biochem Rev 2010; 31:31-38.
4. Kanthan R, Senger JL, Kanthan SC. Molecular Events in Primary and Metastatic Colorectal Carcinoma: A Review. Pathol Res Int 2012; 2012:597497
5. Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 2014; 42:124-139.
6. Bertout JA, Patel SA, Simon MC. The impact of 02 availability on human cancer. Nat Rev Cancer 2008; 8:967-975.
7. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11:393-410.
8. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cel 2010; 40:294-309.
9. Semenza GL. Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology. Annu Rev Pathol 2013; 9:47-71 (b).
10. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123:3664-3371 (a).
11. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-634.
12. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33; 207-214.
13. Keith B, Johnson RS, Simon MC. HIFlalpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12; 9-22.
14. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5; 343-354.
15. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30; 393-402.
16. Conteduca V, Sansonno D, Russi S., Dammacco F. Precancerous colorectal lesions (Review). Int J Oncol 2013; 43:973-984.
17. Kim TM, Lee SH, Chung YJ. Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol 2008; 19:6784-6793.
18. Jiang YA, Fan LF, Jiang CQ et al. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J Gastroenterol 2003; 9:491-494.
19. Simiantonaki N, Taxeidis M, Jayasinghe C., Kurzik-Dumke U, Kirkpatrick CJ. Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer 2008; 8:320.
20. Greijer AE, Delis-van Diemen PM, Fijneman RJA et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 2008; 452:535-544.
21. Fan LF, Dong WG, Jiang C.Q., Qian Q., Yu QF. Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression. Int J Colorectal Dis 2008; 23:1057-1064.
22. Baltaziak M, Wincewicz A, Kanczuga-Koda L et al. The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer. Folia Histochem Cytobiol 2013; 51:320-325.
23. Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor 1. Cancer Res 2003; 63:1138-1143.
24. Giles RH, Lolkema MP, Snijckers CM et al. Interplay between VHL/HIFlalpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 2006; 25:3065-3070.
25. Kuwai T, Kitadai Y, Tanaka S., Hiyama T, Tanimoto K, Chayama K. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1 alpha. Cancer Sci 2004; 95:149-153.
26. Zhuang Z, Emmert-Buck MR, Roth MJ. Von Hippel-Lindau disease gene deletion detected in microdis-sected sporadic human colon carcinoma specimens. Hum Pathol 1996; 27:152-156.
27. Newton IP, Kenneth NS, Appleton P.L., Inke Näthke I, Rocha S. Adenomatous Polyposis Coli and Hypoxia-inducible Factor-lalpha have an antagonistic connection. Mol Biol Cell 2010; 21:3630-3638.
28. Näthke I, Rocha S. Antagonistic crosstalk between APC and HIF-la. Cell Cycle 2010; 10:1545-1547.
29. Powell SM, Zilz N, Beazer-Barclay Y, Bryan T.M., Hamilton SR., Thibodeau SN. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-237.
30. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007; 9:210-217.
31. Chi JT, Wang Z, Nuyten DS et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3:e47.
32. Cao D, Hou M, Guan Y.S., Jiang M., Yang Y, Gou H. Expression of HIF-lalpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 2009; 9:432.
33. Kwon HC, Kim SH, Oh SY. Clinicopathological Significance of p53, Hypoxia-inducible Factor lalpha, and Vascular Endothelial Growth Factor Expression in Colorectal Cancer. Anticancer Res 2010; 30:4163-4168 (a).
34. Lu XG, Xing CG, Feng Y.Z., Chen J., Deng C. Clinical significance of immunohistochemical expression of hypoxia-inducible factor-lalpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer 2006; 5:350-353.
35. Theodoropoulos GE, Lazaris AC, Theodoropoulos VE et al. Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. Int J Colorectal Dis 2006; 21:248-257.
36. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007; 37:878-886.
37. Kuo LJ, Hung CS, Chen W.Y., Chang YJ, Wei PL. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth. J Surg Res 2013; 185:264-272.
38. Kwon HC, Kim SH, Oh SY et al. Clinicopathological significance of p53, hypoxia-inducible factor lalpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res 2010; 30:4163-4168.
39. Jiang CQ, Fan LF, Liu ZS et al. Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma. Chin Med J 2004; 117:1541-1546.
40. Kuwai T, Kitadai Y, Tanaka S et al. Expression of HIF-lalpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003; 105:176-181.
41. Yoshimura H, Dhar DK, Kohno H et al. Prognostic Impact of Hypoxia-Inducible Factors lalpha and 2alpha in Colorectal Cancer Patients: Correlation with Tumor Angiogenesis and Cyclooxygenase-2 Expression. Clin Cancer Res 2004; 10:8554-8560.
42. Yu JX, Cui L, Zhang QY et al. Expression of NOS and HIF-la in human colorectal carcinoma and implication in tumor angiogenesis. World J Gastroenterol 2006; 12:4660-4466.
43. Kwon HC, Kim SH, Oh SU et al. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci 2010; 101:1557-1561 (b).
44. Calvani M, Trisciuoglio D, Bergamaschi D., Shoemaker RH, Melillo G. Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells. Cancer Res 2008; 68:285-291.
45. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
46. Khong TL, Thairu N, Larsen H., Dawson PM, Kiriakidis S, Paleolog EM. Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer 2013; 13:518.
47. Rigopoulos DN, Tsiambas E, Lazaris AC et al. Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis. JBUON 2010; 15:107-115.
48. Thomaidis T, Maderer A, Formentini A et al. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. J Exp Clin Cancer Res 2014; 33:83-93.
49. Kaidi A, Qualtrough D, Williams A.C., Paraskeva C. Direct Transcriptional Up-regulation of Cyclooxygen-ase-2 by Hypoxia-Inducible Factor (HIF)-1 Promotes Colorectal Tumor Cell Survival and Enhances HIF-1 Transcriptional Activity during Hypoxia. Cancer Res 2006; 66:6683-6691.
50. Wincewicz A, Sulkowska M, Koda M., Sulkowski S. Clinicopathological Significance and Linkage of the Distribution of HIF-1α and GLUT-1 in Human Primary Colorectal Cancer. Pathol Oncol Res 2007; 13:15-20.
51. Imamura T, Kikuchi H, Herraiz MT et al. HIF-la and HIF-2a have divergent roles in colon cancer. Int J Cancer 2009; 124:763-771.
52. Pez F, Dayan F, Durivault J et al. The HIF-1-Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth. Cancer Res 2011; 71:1647-1657.
53. Zhao XY, Chen TT, Xia L et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis 2010; 31:1367-1375.
54. Van der Bilt JD, Soeters ME, Duyverman AM et al. Perinecrotic Hypoxia Contributes to Ischemia/Reperfusion-Accelerated Outgrowth of Colorectal Micro-metastases. Am J Pathol 2007; 170:1379-1388.
55. Koukourakis MI, Giatromanolaki A, Harris A.L., Sivridis E. Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. Cancer Res 2006; 66:632-637.
56. Zhang W, Wu Y, Yan Q et al. Desferoxamine enhances cell migration and invasion through promotion of HIF-la expression and epithelial mesenchymal transition in colorectal cancer. Oncol Rep 2014; 31:111-116.
57. Shimomura M, Hinoi T, Kuroda S et al. Overexpression of Hypoxia Inducible Factor-1 Alpha is an Independent Risk Factor for Recurrence After Curative Resection of Colorectal Liver Metastases. Ann Surg Oncol 2013; 3:527-536.
58. Rajaganeshan R, Prasad R, Guillou P.J., Scott N., Poston G, Jayne DG. Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 2009; 35:1286-1294.
59. Sulkowska M, Wincewicz A, Sulkowski S., Koda M, Kanczuga-Koda L. Relations of TGF-betal with HIF-1 alpha, GLUT-1 and longer survival of colorectal cancer patients. Pathology 2009; 41:254-260.
60. Furlan D, Sahnane N, Carnevali I. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 2008; 39:1483-1494.
61. Rajaganeshan R, Prasad R, Guillou P.J., Poston G., Scott N, Jayne DG. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis 2008; 23:1049-1055.
62. Koukourakis MI, Giatromanolaki A, Simopoulos C., Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005; 22:25-30.
63. Murono K, Tsuno NH, Kawai K. SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIFlalpha. Anticancer Res 2012; 32:865-872.
64. Shioya M, Takahashi T, Ishikawa H et al. Expression of hypoxia-inducible factor 1 alpha predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer. J Radiat Res 2011; 52:821-827.
65. Roberts DL, Williams KJ, Cowen RL et al. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 2009; 101:1290-1297.
66. Chen Z, He X, Xia W., Huang J. Prognostic Value and Clinicopathological Differences of HIFs in Colorectal Cancer: Evidence from Meta-Analysis. PLoS ONE 2013; 8:e80337.
67. Ioannou M, Mylonis I, Kouvaras E et al. Validated analysis of HIF-1alpha expression in cancer cells using a controlled and comparative immunoassay. Oncol Rep 2010; 24:161-169.
68. Baba Y, Nosho K, Shima K. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010; 176:2292-2301.
69. Hertogh G De, Geboes KP. Practical and Molecular Evaluation of Colorectal Cancer New Roles for the Pathologist in the Era of Targeted Therapy. Arch Pathol Lab Med 2010; 134:853-863.
70. Hohla F, Winder T, Greil R., Rick FG, Block NL, Schally AV Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol 2014; 20:6102-6112.
71. Waldner MJ, Neurath MF. The molecular therapy of colorectal cancer. Mol Aspects Med 2010; 31:171-178.
72. Deschoolmeester V, Baay M, Specenier P., Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010; 15:699-731.
73. Kumar R. Commentary: targeting colorectal cancer through molecular biology. Semin Oncol 2005; 9:37-39.
74. Luwor RB, Lu Y, Li X., Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005; 24:4433-4441.
75. Lu Y, Liang K, Li X., Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to down-regulation of hypoxia-inducible factor-lalpha. Mol Cancer 2007; 6:63-75.
76. Li X, Lu Y, Liang K., Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-lalpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 2008; 7:1207-1217.
77. Saridaki Z, Georgoulias V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 2010; 16:1177-1187.
78. Lievre A, Bachet JB, Le Corre D et al. KRAS mutaüon status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995.
79. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379.
80. Mizukami Y, Li J, Zhang X., Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004; 64:1765-1772.
81. Mizukami Y, Fujiki K, Duerr EM et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 281:13957-13963.
82. Kikuchi H, Pino MS, Zeng M, Shirasawa S., Chung DC. Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-Inducible Factor-1α and -2α in Colon Cancer. Cancer Res 2009; 69:8499-8506.